Efficient synthesis of antifungal pyrimidines via palladium catalyzed Suzuki/Sonogashira cross-coupling reaction from Biginelli 3,4-dihydropyrimidin-2(1H)-ones

Regioselective addition reactions at C-2 of 3,4-dihydropyrimidinones. Synthesis and evaluation of multifunctionalized tetrahydropyrimidines

“…25 Similarly, pyrimidines have been reported via palladium catalyzed Suzuki Sonogashira cross-coupling and Eschenmoser sulfide contraction reactions. 26,27 However, these useful approaches are multistep as well as involve expensive reagents and lack generality in many instances. Regioselective addition reactions at C-2 position of DHPMs appeared to be an attractive tool for introducing diversity at the C-2 position in order to probe the effect of substitution on the cytostatic activity.…”

Pyrazole Based Inhibitors against Enzymes of Staphylococcus aureus: A Computational Study

“…Pyrazole and pyrazolones ring system plays an imperative role in wide range of biological activities such as antibacterial [11,12], antifungal [13], antimalarial [14], anticonvulsant, antitumor [15] and anti-inflammatory agents [16]. It is also interesting to note that pyrazoles are reported as well-known pharmacophores in targeting many diseases and in specific a potent Cannabinoid inhibitors are designed using pyrazole scaffold [17][18][19][20].…”

Synthesis of novel pyrazole and pyrimidine derivatives bearing sulfonamide moiety as antitumor and radiosensitizing agents

“…With growing application on their synthesis and bioactivity, chemists and biologists in recent years have directed considerable attention on the research of pyrazole derivatives. Pyrimidines are of chemical and pharmacological interest and compounds containing the pyrimidine ring system have been shown to possess antibacterial (Deshmukh et al, 2009), antifungal (Gholap et al, 2008), antimalarial (Azas et al 2003), anticonvulsant (Said et al 2009), and antitumor activities (Noll et al, 2009). Some are valuable drugs for the treatment of acute leukemia in children and adult granulocytic leukemia (Noll et al, 2009).…”